According to the SEC form, JanuaryAI received $13 million in the debt financing.
The Board of Directors of Brighter AB has today, with authorization from the general meeting in the Company on June 8, 2022, decided to carry out of an issue of units consisting of shares and warrants with preferential rights for existing shareholders of approximately SEK 52.4 million
DELHI-BASED DIABETES MONITORING platform BeatO has raised Rs 18 crore from Alteria Capital as debt in the Series B funding round. With this, the company has received financing for the second time this year. The company raised debt worth Rs 27 crore in April this year led by existing backers W Health Global LLC, Kotak Investments, and Sage Hill Investors.
Medtronic plc today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. has closed a registered public offering of €500,000,000 principal amount of 2.625% Senior Notes due 2025, €1,000,000,000 principal amount of 3.000% Senior Notes due 2028, €1,000,000,000 principal amount of 3.125% Senior Notes due 2031 and €1,000,000,000 principal amount of 3.375% Senior Notes due 2034. The net proceeds from the Offering are approximately €3.47 billion, after deducting underwriting discounts and commissions and estimated expenses related to the Offering payable by Medtronic Luxco.
BeatO, on November 16, announced to have raised $33 million in a series B round of funding that was led by Lightrock India with participation from HealthQuad, Flipkart and the company’s existing investors.
Canada's Diabetes Market will reach US$ 1.53 Billion by 2028 with a CAGR of 3.85% during the forecast period (2023-2028), according to the publisher.
#cgm
#bgm
#insulin pump
When Second Sight Medical and Nano Precision Medical merged last year, the rebranded company — Vivani Medical (Nasdaq:VANI)— had a goal: bring a six-month, subdermal drug delivery implant that treats conditions including type 2 diabetes to market. CEO Dr. Adam Mendelsohn leads the way for the developer of the proprietary NanoPortal technology.
Eli Lilly and Company (NYSE: LLY) today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at $35 or less per month. Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable insulin.
Mednow Inc. announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital diabetes management solution, to enable convenient on-demand access to Dexcom G6 real-time continuous glucose monitoring supplies and personalized diabetes care services. The Mednow clinical team will utilize the Dexcom Clarity data platform, to integrate individual glucose patterns and trends into personalized coaching and care.
#institution
#cgm
#rpm
Nutrition tracking app, Cronometer, will now integrate with Dexcom, the global leader in real-time continuous glucose monitoring (CGM). In the latest version of the Cronometer app, users residing in the U.S.A. will be able to import Dexcom CGM data and self-reported insulin data into their Cronometer accounts. The integration will allow Cronometer users to chart their glucose levels and insulin use over time. Cronometer Gold subscribers will also be able to use the Custom Charts feature to plot glucose or insulin data against specific nutrient intake, such as carbs, to help identify trends associated with their diet.
#connected device
#mobile app
#cgm